GITR's Series A Round

GITR raised a round of funding on May 08, 2015. Investors include HealthCare Ventures.

GITR is developing TRX518, a First-in-Class humanized monoclonal antibody that is reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR), for the treatment of cancer. TRX518 is…

Articles about GITR's Series A Round: